Luciano Ibba
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 87 publications
Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).
Journal: Dermatology and therapy
Published: July 14, 2026
Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study.
Journal: Dermatology and therapy
Published: May 05, 2026
JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study.
Journal: Dermatology and therapy
Published: April 24, 2026
Dose Adjustment of JAK Inhibitors for the Management of Moderate-to-Severe Atopic Dermatitis: A Single-Centre Retrospective Study.
Journal: Medicina (Kaunas, Lithuania)
Published: April 13, 2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study.
Journal: Dermatology and therapy
Published: March 04, 2026
Dose escalation and personalization in atopic dermatitis: reply to the real-world study by Demirbaş et al. "Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort.".
Journal: The Journal of dermatological treatment
Published: February 06, 2026
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort.
Journal: The Journal of dermatological treatment
Published: January 23, 2026
Lebrikizumab After Multiple Prior Advanced Therapies in Moderate-To-Severe Atopic Dermatitis: A Real-World Case Series.
Journal: International journal of dermatology
Published: January 02, 2026
Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis).
Journal: Dermatology and therapy
Published: December 26, 2025
Tildrakizumab in Managing Psoriasis with Involvement of Difficult-to-Treat Areas: A Multicenter Real-Life Retrospective Study.
Journal: Journal of clinical medicine
Published: December 21, 2025
Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement.
Journal: Dermatology and therapy
Published: December 19, 2025
JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.
Journal: Medicina (Kaunas, Lithuania)
Published: December 14, 2025
Last Updated: 09/26/2026